These data supported GIPR antagonism for obesity while GIP receptor agonism was thought to be ineffective for glucose lowering in T2D patients and potentially deleterious for body weight (65, 66). The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.